Colin Bristow
Stock Analyst at UBS
(1.96)
# 1,940
Out of 4,667 analysts
84
Total ratings
35.71%
Success rate
-5.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $562 → $586 | $451.23 | +29.87% | 13 | Nov 5, 2024 | |
| AMGN Amgen | Maintains: Neutral | $335 → $326 | $287.87 | +13.25% | 7 | Oct 31, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $142 → $136 | $97.44 | +39.57% | 5 | Oct 9, 2024 | |
| BIIB Biogen | Maintains: Neutral | $234 → $202 | $156.00 | +29.49% | 10 | Oct 3, 2024 | |
| PTCT PTC Therapeutics | Upgrades: Buy | $47 | $41.96 | +12.01% | 2 | Aug 26, 2024 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $25 → $4 | $1.21 | +230.58% | 4 | Aug 16, 2024 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $14 → $6 | $2.37 | +153.16% | 3 | Aug 15, 2024 | |
| IMVT Immunovant | Maintains: Buy | $42 → $41 | $26.17 | +56.67% | 5 | Aug 13, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $3.5 → $1 | $0.59 | +70.07% | 5 | Aug 9, 2024 | |
| PFE Pfizer | Maintains: Neutral | $30 → $31 | $24.94 | +24.30% | 8 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $743.35 | +47.84% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $81 → $75 | $88.63 | -15.38% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $7.50 | +393.33% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $54 | $13.04 | +314.11% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $110.86 | +50.64% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $753.41 | -44.25% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $6.03 | -66.83% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.65 | +990.91% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $167.76 | -12.97% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $57.88 | +29.58% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $4.05 | +541.98% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $3.98 | +126.13% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $195 | $0.39 | +50,157.73% | 2 | Feb 1, 2021 |
Vertex Pharmaceuticals
Nov 5, 2024
Maintains: Buy
Price Target: $562 → $586
Current: $451.23
Upside: +29.87%
Amgen
Oct 31, 2024
Maintains: Neutral
Price Target: $335 → $326
Current: $287.87
Upside: +13.25%
Merck & Co.
Oct 9, 2024
Maintains: Buy
Price Target: $142 → $136
Current: $97.44
Upside: +39.57%
Biogen
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $156.00
Upside: +29.49%
PTC Therapeutics
Aug 26, 2024
Upgrades: Buy
Price Target: $47
Current: $41.96
Upside: +12.01%
ALX Oncology Holdings
Aug 16, 2024
Maintains: Buy
Price Target: $25 → $4
Current: $1.21
Upside: +230.58%
Acumen Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $14 → $6
Current: $2.37
Upside: +153.16%
Immunovant
Aug 13, 2024
Maintains: Buy
Price Target: $42 → $41
Current: $26.17
Upside: +56.67%
BioXcel Therapeutics
Aug 9, 2024
Maintains: Neutral
Price Target: $3.5 → $1
Current: $0.59
Upside: +70.07%
Pfizer
Jul 31, 2024
Maintains: Neutral
Price Target: $30 → $31
Current: $24.94
Upside: +24.30%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $743.35
Upside: +47.84%
Apr 17, 2024
Maintains: Neutral
Price Target: $81 → $75
Current: $88.63
Upside: -15.38%
Mar 28, 2024
Initiates: Buy
Price Target: $37
Current: $7.50
Upside: +393.33%
Mar 1, 2024
Maintains: Buy
Price Target: $56 → $54
Current: $13.04
Upside: +314.11%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $110.86
Upside: +50.64%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $753.41
Upside: -44.25%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $6.03
Upside: -66.83%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $1.65
Upside: +990.91%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $167.76
Upside: -12.97%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $57.88
Upside: +29.58%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $4.05
Upside: +541.98%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $3.98
Upside: +126.13%
Feb 1, 2021
Initiates: Neutral
Price Target: $195
Current: $0.39
Upside: +50,157.73%